Target
NKG2D ligands
2 products, 2 indications
Indications
glioblastoma (2 products)
Newly diagnosed glioblastoma or anaplastic astrocytoma (1 products)
Loading...
2 drugs
5 abstracts
Abstract
INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).Org: In8bio, University of Alabama at Birmingham Comprehensive Cancer Center, In8bio, Inc, In8Bio, Inc.,
Abstract
INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).Org: In8bio, Inc, In8bio, In8Bio, Inc., University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion.Org: Medical Imaging Center of Southern California, NKGen Biotech Inc.,
Abstract
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.Org: Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, City of Hope Comprehensive Cancer Center, City of Hope Beckman Research Institute, Cytoimmune Therapeutics,
Abstract
The clinical impact of soluble natural killer cell group 2-member D (NKG2D) receptor ligands on tumor tumorigenicity and anti-tumor immunity.Org: Northwestern Medicine Cancer Center Warrenville, Bristol Myers Squibb, Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,